September 17, 2025

expert reaction to an unpublished conference abstract on a new RNA-based weight loss drug aimed at altering metabolism to provide longer-term weight loss

An unpublished conference abstract presented at the European Association for the Study of Diabetes (EASD) looks at a new RNA-based weight loss drugs which aims to alter metabolism for long term weight loss. 

Dr Adam Collins, Associate Professor of Nutrition, University of Surrey, said:

“Without a full peer-reviewed paper it is difficult to comment on the study however, I would be wary of claims of “reprogramming metabolism”.

“I think mechanistically this is speculative, without knowing the direct effects this is having on adipose tissue (fat cells) storage, and mitochondrial function  (e.g. fat burning and thermogenesis).  Even then, the exact molecular mechanisms behind these effects remain unclear. 

“It is essential to see the full paper, to understand the mechanistic rationale behind the RES-10, and its proven metabolic effects. Before interpreting any overall weight loss results.”

‘Reprogramming obesity: preclinical development and phase 1 study design of RES-010, a novel miRNA-targeting therapy’ by Nitsche et al. is being presented at the EASD conference. The embargo lifted at 23:01 UK time Wednesday 17^th September 2025.

Declared interests

For all experts, no reply to our request for DOIs was received.